Breaking News Instant updates and real-time market news.

CREE

Cree

$39.39

-1 (-2.48%)

, SIX

Six Flags

$59.17

-1.62 (-2.66%)

19:02
04/24/18
04/24
19:02
04/24/18
19:02

On The Fly: After Hours Movers

UP AFTER EARNINGS: Cree (CREE) up 7.8%... Six Flags (SIX) up 6.5%... Texas Instruments (TXN) up 4.6%... Usana (USNA) up 4.4%... MKS Instruments (MKSI) up 4.2%... Supervalue (SVU) up 3.5%... iRbotot (IRBT) up 3.3%... DDR Corp (DDR) up 3.1%... Inphi (IPHI) up 3.1%... Hawaiian Holdings (HA) up 2.2%. ALSO HIGHER: Shire (SHPG) up 4.2% after reports of pending deal with Takeda... Knowles Corp (KN) up 1.8% after S&P SmallCap600 entry. DOWN AFTER EARNINGS: Teradyne (TER) down 10.2%... Edwards Lifesciences (EW) down 8.2%... Dolby (DLB) down 5.9%... Wynn Resorts (WYNN) down 2.9%... Capital One (COF) down 2.6%. ALSO LOWER: Sangamo (SGMO) down 6.2% after equity offering... Mirati Therapeutics (MRTX) down 4.1% after sitravatinib update.

CREE

Cree

$39.39

-1 (-2.48%)

SIX

Six Flags

$59.17

-1.62 (-2.66%)

TXN

Texas Instruments

$98.33

0.25 (0.25%)

USNA

USANA

$95.93

0.175 (0.18%)

MKSI

MKS Instruments

$102.85

-3.35 (-3.15%)

SVU

Supervalu

$14.61

-0.02 (-0.14%)

IRBT

iRobot

$59.10

-0.85 (-1.42%)

DDR

DDR Corp.

$6.68

0.025 (0.38%)

IPHI

Inphi

$31.46

1.1 (3.62%)

HA

Hawaiian Holdings

$39.20

-0.3 (-0.76%)

SHPG

Shire

$164.05

3.97 (2.48%)

KN

Knowles

$11.01

-0.575 (-4.97%)

TER

Teradyne

$41.50

1.06 (2.62%)

EW

Edwards Lifesciences

$134.63

-2.59 (-1.89%)

DLB

Dolby

$65.85

-1.4 (-2.08%)

WYNN

Wynn Resorts

$189.70

-3.54 (-1.83%)

COF

Capital One

$97.41

-0.115 (-0.12%)

SGMO

Sangamo

$17.85

-0.3 (-1.65%)

MRTX

Mirati Therapeutics

$28.25

-0.15 (-0.53%)

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 03

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 29

    May

  • 30

    May

  • 12

    Jun

  • 14

    Aug

  • 21

    Dec

  • 26

    Apr

CREE Cree
$39.39

-1 (-2.48%)

01/25/18
DBAB
01/25/18
NO CHANGE
Target $45
DBAB
Buy
Read-through from STMicroelectronics earnings positive for Cree, says Deutsche Bank
Deutsche Bank analyst Vishal Shah notes that STMicroelectronics (STM) announced earnings, highlighting some significant opportunities for Silicon Carbide, specifically in EVs. The analyst believes that management's comments on the call about increasing SiC device capacity to meet strong customer demand for SiC is also positive for Cree's (CREE) SiC power device segment. Further, Shah sees upside to current estimates resulting from stronger than expected demand for SiC in EVs, as highlighted during both companies' earnings calls. He reiterates a Buy rating and $45 price target on Cree's shares.
02/07/18
JPMS
02/07/18
NO CHANGE
Target $28
JPMS
Underweight
Cree removed from Analyst Focus List as short idea at JPMorgan
JPMorgan analyst Paul Coster removed Cree from his firm's Analyst Focus List as a short idea. Cree is no longer one of his firm's highest conviction short ideas with the stock down 18.5% since mid-December. Coster keeps an Underweight rating on the name with a $28 price target.
03/07/18
GSCO
03/07/18
UPGRADE
Target $39
GSCO
Neutral
Cree upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Brian Lee upgraded Cree to Neutral and raised his price target for the shares to $39 from $31. The company's transformation at the Wolfspeed segment is progressing more quickly than expected, Lee tells investors in a research note. He believes, however, that the stock's valuation "still appears challenging."
03/20/18
DBAB
03/20/18
NO CHANGE
Target $52
DBAB
Buy
Cree price target raised to $52 from $45 at Deutsche Bank
Deutsche Bank analyst Vishal Shah raised his price target for Cree to $52 to reflect his increased estimates post the acquisition of Infineon's RF power business. The analyst sees "significant upside" to consensus estimates on the expected takeoff of the 4G+/5G market demand beyond the 2020 timeframe and Wolfspeed's ability to gain market share with its new RF assets. He keeps a Buy rating on Cree.
SIX Six Flags
$59.17

-1.62 (-2.66%)

10/05/17
10/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mallinckrodt (MNK) downgraded to Hold from Buy at Canaccord with analyst Dewey Steadman saying he sees a lack of near-term catalysts and believes the story will take time to evolve. 2. GrubHub (GRUB) downgraded to Neutral from Buy at Citi with analyst Mark May citing valuation with the shares up 44% year-to-date. 3. Coach (COH) downgraded to Neutral from Overweight at Piper Jaffray with analyst Erinn Murphy saying the stock is likely to enter a "period of digestion" as the company integrates Kate Spade and as investors "grapple with" its new reporting structure. 4. PNC Financial (PNC) downgraded to Equal Weight from Overweight at Stephens with analyst Terry McEvoy saying he views the shares as fairly valued following the stock's outperformance relative to Super Regional bank peers year-to-date. 5. Six Flags (SIX) downgraded to Long-Term Buy from Buy at Hilliard Lyons with analyst Jeffrey Thomison citing recent share appreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/18
WEDB
01/08/18
NO CHANGE
Target $76
WEDB
Outperform
Six Flags price target raised to $76 from $67 at Wedbush
Wedbush analyst James Hardiman raised his price target for Six Flags to $76 from $67 based on a 4.2% dividend yield on his estimated 2018 dividend payout of $3.18. Further, the analyst believes that Six Flags should benefit from news flow over the course of 2018. Hardiman reiterates an Outperform rating on the shares.
02/21/18
STFL
02/21/18
NO CHANGE
Target $78
STFL
Buy
Six Flags selloff a buying opportunity, says Stifel
Stifel analyst Steven Wieczynski attributes Six Flags' post-earnings selloff to three factors: management comments on its partner in Dubai being in arrears on payments related to its international licensing arrangement; the fact that Q4 visitation decreased 3% year-over-year; and the absence of buyback activity in the quarter. However, he views the selloff as a buying opportunity as he believes 2018 is shaping up to be another strong operating year and has the sense the company remains active in pursuit of additional international licensing agreements. Wieczynski raised his price target on Six Flags shares to $78 from $72 and keeps a Buy rating on the stock.
10/05/17
HDLY
10/05/17
DOWNGRADE
HDLY
Long-Term Buy
Six Flags downgraded to Long-Term Buy from Buy at Hilliard Lyons
Hilliard Lyons analyst Jeffrey Thomison downgraded Six Flags to Long-Term Buy with a $69 price target citing recent share appreciation.
TXN Texas Instruments
$98.33

0.25 (0.25%)

04/04/18
UBSW
04/04/18
INITIATION
Target $85
UBSW
Sell
Texas Instruments initiated with a Sell at UBS
UBS started Texas Instruments with a Sell rating and $85 price target.
04/02/18
STFL
04/02/18
NO CHANGE
Target $115
STFL
Hold
Texas Instruments tracking well towards March quarter guidance, says Stifel
After having recently traveled with Texas Instruments management, Stifel analyst Tore Svanberg said he believes the company is tracking well towards its guidance for the March quarter, given relative strength continuing from its Automotive and Industrial markets. The analyst, who also thinks the company's new U.S. tax rate could drive material improvement to its long-term free cash flow generation, keeps a Hold rating and $115 price target on Texas Instruments shares.
03/27/18
LBOW
03/27/18
INITIATION
LBOW
Neutral
Texas Instruments initiated with a Neutral at Longbow
Longbow analyst Shawn Harrison started Texas Instruments with a Neutral rating. The analyst believes the current valuation captures the company's "robust" free cash flow generation.
04/05/18
04/05/18
NO CHANGE

UBS starts Semiconductors coverage, says sell Micron, Texas Instruments
UBS analyst Timothy Arcuri started coverage on the U.S. Semiconductors and Semi Equipment sector, expressing the view that consolidation and a slowdown in Moore's Law should actually lead to pricing power and inflationary effects that are still in the early innings. However, he also believes semis are still cyclical and sees some signs of caution moving into later 2018 and 2019. Arcuri, who is cautious on the memory cycle in the near-term, started Micron (MU) with a Sell rating and $35 price target, citing those cyclical memory concerns. He also has one other Sell rating among his 14 recommendations, on Texas Instruments (TXN), citing its fading leverage, a more level playing field for capital return and his cyclical concerns. Among the 14 stocks he initiated, Arcuri has 4 Buy ratings - Intel (INTC), given his above consensus call for datacenter group growth and what he sees as a mispricing of long-term growth potential; Marvell (MRVL) and Broadcom (AVGO), which he views as transformation stories; and KLA-Tencor (KLAC), on its migration to industrial tech and exposure to AI-related compute growth.
USNA USANA
$95.93

0.175 (0.18%)

04/23/18
04/23/18
DOWNGRADE

Hold
Follow-up: USANA downgraded to Hold on valuation at Pivotal Research
As previously reported, Pivotal Research downgraded USANA to Hold from Buy. Analyst Timothy Ramey changed his rating citing valuation and maintained a $95 price target.
01/24/18
SIDC
01/24/18
DOWNGRADE
SIDC
Neutral
USANA downgraded to Neutral from Buy at Sidoti
04/23/18
PIVT
04/23/18
DOWNGRADE
PIVT
Hold
USANA downgraded to Hold from Buy at Pivotal Research
05/03/17
PIVT
05/03/17
UPGRADE
Target $75
PIVT
Buy
USANA upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Timothy Ramey upgraded USANA to Buy from Hold, stating that the company's detailed five-point rebuttal to the major claims made by a recent short report allays the concerns that were raised. He set a $75 price target on USANA shares, up from his prior $55 target.
MKSI MKS Instruments
$102.85

-3.35 (-3.15%)

03/22/18
DBAB
03/22/18
NO CHANGE
Target $140
DBAB
Buy
MKS Instruments price target raised to $140 from $130 at Deutsche Bank
Deutsche Bank analyst Sidney Ho raised his price target for MKS Instruments to $140 after meeting with management at the company's headquarters. The company believes 2018 wafer fab equipment spending is slightly better than its forecasts two months ago, Ho tells investors in a research note. The analyst sees a positive longer term trend for WFE spending and keeps a Buy rating on MKS Instruments.
02/01/18
DBAB
02/01/18
NO CHANGE
Target $130
DBAB
Buy
MKS Instruments price target raised to $130 from $116 at Deutsche Bank
Deutsche Bank analyst Sidney Ho raised his price target for MKS Instruments to $130 saying the company's "solid report and guidance" reinforce his view that it is well positioned to continue to outgrow the underlying markets. Ho keeps a Buy rating on the shares.
04/18/18
STFL
04/18/18
NO CHANGE
STFL
Lam reiteration of WFE view not a negative sign, says Stifel
Stifel analyst Patrick Ho acknowledged that Lam Research (LRCX) did not provide any significant "new" news related to 2018 wafer fab equipment spending and reiterated its previous guidance of low double-digit year-over-year growth with only a modest change in mix. However, this reiteration is not a negative sign on the current environment or 2018 as a whole, said Ho, who advises using any selloff in the group following Lam's report as a buying opportunity. He continues to prefer Applied Materials (AMAT) and MKS Instruments (MKSI) as his most preferred names in Semiconductor Capital Equipment, while also having Buy ratings on Lam Research and Entegris (ENTG).
02/02/18
STFL
02/02/18
NO CHANGE
STFL
Apple won't be dominant catalyst for semi, display spending, says Stifel
Stifel analyst Patrick Ho believes Apple (AAPL) will remain a key catalyst, but not the dominant catalyst, for semiconductor and display spending, citing the emerging market opportunities in many different markets, such as data centers, artificial intelligence, autonomous driving, cryptocurrency, and VR/AR. Ho said he remains "steadfast" in the view that Applied Materials (AMAT) is the best positioned company to benefit from these emerging semi and display trends, given its positioning in terms of 3D NAND and strength in the foundry segment. He also sees Lam Research (LRCX) benefiting on the memory front and KLA-Tencor (KLAC) on the advanced foundry/logic front and views suppliers like MKS Instruments (MKSI) and Entegris (ENTG) as also poised to benefit.
SVU Supervalu
$14.61

-0.02 (-0.14%)

04/05/18
GSCO
04/05/18
NO CHANGE
Target $14
GSCO
Sell
Supervalu maintained a Sell, target to $14 at Goldman Sachs
Goldman analyst Christopher Prykull retierated his Sell rating on Supervalue and trimmed his price target to $14 from $15 saying he continues to have fundamental concerns across each segment. Prykull acknowledges risk/reward appears positive near-term with the upcoming sale-leaseback update likely on the Q4 report, but said the secular backdrop for independent grocery and competition remains fierce.
11/14/17
GSCO
11/14/17
INITIATION
Target $14
GSCO
Sell
Supervalu assumed with a Sell at Goldman Sachs
Goldman analyst Christopher Prykull assumed coverage on Supervalu with a Sell and $14 price target. Prykull expects retail to underperform given increasing competition, pricing gaps, and under-investment in stores and said Wholesale faces a challenged end market. The analyst also sees EBITDA headwinds from waning transition service agreement revenue and limited cost offsets.
11/14/17
11/14/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kroger (KR) assumed with a Neutral at Goldman Sachs. 2. Dollar General (DG) assumed with a Neutral at Goldman Sachs. 3. Sea Limited (SE) was initiated with an Outperform at Cowen, an Overweight at Piper Jaffray, a Buy at Goldman Sachs and Stifel, and an Equal Weight at Morgan Stanley. 4. Supervalu (SVU) assumed with a Sell at Goldman Sachs. 5. Celanese (CE) initiated with a Buy at Tudor Pickering. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/18
FBCO
04/17/18
INITIATION
FBCO
Underperform
Supervalu initiated with an Underperform at Credit Suisse
Credit Suisse analyst Judah Frommer initiated Supervalu with an Underperform rating and $15 price target, saying he sees limited ability to grow EBITDA in the near term due to an inferior customer base, as well as lost Albertsons TSA revenue.
IRBT iRobot
$59.10

-0.85 (-1.42%)

04/19/18
04/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Walmart (WMT) upgraded to Buy from Hold at Argus with analyst Christopher Graja saying he believes an improving job market should help low-and-middle-income shoppers spend more. 2. Sprint (S) upgraded to Neutral from Underperform at Macquarie. 3. iRobot (IRBT) upgraded to Overweight from Neutral at Piper Jaffray with analyst Troy Jensen saying tracking data shows iRobot is experiencing "exceptionally strong demand in North America." 4. Diodes (DIOD) upgraded to Buy from Neutral at Longbow with analyst Shawn Harrison saying he expects rising demand, pricing, and Pericom growth to drive sales, gross margins, and earnings higher. 5. Texas Capital (TCBI) upgraded to Overweight from Neutral at Piper Jaffray with analyst Brett Rabatin saying he sees Texas Capital outperforming peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/28/18
NORL
02/28/18
NO CHANGE
Target $86
NORL
Outperform
Buying iRobot would be 'logical next step' for Amazon, says Northland
After Amazon (AMZN) acquired a smart camera company Blink last year and reportedly agreed this week to buy smart security company Ring, Northland analyst Michael Latimore said he thinks a "logical next step" would be for the e-commerce giant to buy iRobot (IRBT) and add more smart home products to sell. The analyst, who said he expects additional color tomorrow during the company's analyst day on their "rich AI tech" and product roadmap, has an Outperform rating on iRobot shares.
04/18/18
PIPR
04/18/18
UPGRADE
PIPR
Overweight
iRobot upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Troy Jensen upgraded iRobot to Overweight from Neutral and increased his price target to $78 from $63. Jensen said that tracking data shows iRobot is experiencing "exceptionally strong demand in North America," and he believes the demand is likely share gains for the new Shark and Neato products as well as better than expected demand for Roomba vacuums for the March quarter. Jensen also believes new product introductions in the second half of the year and increased marketing spending in Europe and for the BraavaJet will provide additional tailwinds for iRobot.
02/16/18
02/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Azul (AZUL) initiated with a Buy at UBS. 2. Acer Therapeutics (ACER) initiated with an Outperform at William Blair. 3. iRobot (IRBT) initiated with an Outperform at Northland. 4. At Home Group (HOME) initiated with a Buy at Buckingham. 5. Casey's General Stores (CASY) initiated with a Buy at Gabelli. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DDR DDR Corp.
$6.68

0.025 (0.38%)

12/15/17
SBSH
12/15/17
NO CHANGE
Target $11
SBSH
Buy
DDR Corp. a more attractive takeover candidate after spinoff, says Citi
Citi analyst Michael Bilerman said he likes DDR Corp.'s (DDR) plan to spin off assets into a new REIT to be called Retail Value Trust, arguing that the "new DDR" assets are likely worth close to $10-$11 per share and the RVT assets are reasonably worth $2-$3 per share. Given that valuation view, the RVT spin-co assets are essentially "free" to investors, said Bilerman. Additionally, "new DDR" will become a "much more attractive" acquisition candidate with the RVT assets remove, said Bilerman, who keeps a Buy rating on DDR shares.
03/05/18
EVER
03/05/18
DOWNGRADE
EVER
Underperform
DDR Corp. downgraded to Underperform from In Line at Evercore ISI
12/19/17
KEYB
12/19/17
DOWNGRADE
KEYB
Sector Weight
DDR Corp. downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Jordan Sadler downgraded DDR Corp to Sector Weight, saying the REIT is likely to perform comparably to its peers in the near term despite the spin-off of 50 assets which he views to be a positive. Sadler says the REIT's valuation already reflects a challenging environment, but sees uncertainty regarding any potential improvement in the near term.
12/04/17
EVER
12/04/17
DOWNGRADE
EVER
In Line
DDR Corp. downgraded to In Line from Outperform at Evercore ISI
IPHI Inphi
$31.46

1.1 (3.62%)

03/19/18
NORL
03/19/18
DOWNGRADE
NORL
Underperform
Inphi downgraded to Underperform from Market Perform at Northland
04/16/18
JPMS
04/16/18
NO CHANGE
JPMS
Inphi should be bought on ZTE-related selloff, says JPMorgan
JPMorgan analyst Harlan Sur tells investors to buy shares of Inphi (INPI) on weakness after the U.S. Department of Commerce imposed a denial of export privileges against ZTE (ZTCOY). The stock is down 7.5% to $30.33 in midday trading. The analyst believes ZTE represented about 1% of revenue for Inphi in 2017 and estimates ZTE will represent about 2% of revenue in 2018. Inphi's fundamentals are getting set to inflect in the June quarter, Sur tells investors in an intraday research note. He keeps an Overweight rating on the shares.
04/16/18
RILY
04/16/18
NO CHANGE
RILY
Acacia, Oclaro have most direct impact from ZTE ban, says B. Riley FBR
B. Riley FBR analyst David Kang said the optical component companies most directly impacted by the U.S. ban on selling components to Chinese telecom equipment maker ZTE (ZTCOY) are Acacia (ACIA) and Oclaro (OCLR), noting that ZTE represented 30% and 18%, respectively, of their total FY17 annual sales. He identifies Fabrinet (FN) and Inphi (IPHI) as companies that are not directly impacted but likely to see a ripple effect due to supply chain exposure to ZTE. Kang also noted that Finisar (FNSR) and NeoPhotonics (NPTN) supply to Huawei, not ZTE, and he expects they will not be impacted by the announcement.
03/19/18
NORL
03/19/18
DOWNGRADE
Target $21
NORL
Underperform
Inphi downgraded to Underperform at Northland on valuation
As reported earlier, Northland analyst Tim Savageaux downgraded Inphi to Market Perform with a price target of $21, citing a 40% recovery in the stock price despite a "much worse than feared" guidance for the March quarter. The analyst says the stock price now fully discounts the company's recovery to $1.50-$2.00 EPS view without discounting the risks around potential ColorZ replacement through the emerging 400G ZR standard and competition for the company's Coherent applications.
HA Hawaiian Holdings
$39.20

-0.3 (-0.76%)

03/08/18
03/08/18
UPGRADE
Target $49

Buy
Hawaiian Holdings upgraded to Buy on higher 2019 estimates at Sidoti
As previously reported, Sidoti analyst Stephen O'Hara upgraded Hawaiian Holdings to Buy from Neutral. He reduced his 2018 EPS estimates as he expects into-service delays for some of its A321NEOs will have a minor negative impact, but he sees the company's EPS beginning to rebound in 2019. O'Hara, who sees 2019 benefitting from more modest competitive capacity growth than 2018, raised his 2019 estimates and increased his price target on Hawaiian Holdings shares to $49 from $45.
04/10/18
IMPC
04/10/18
NO CHANGE
IMPC
Hawaiian outperforms industry on unit revenues in Q1, says Imperial
Imperial Capital analyst Megan Barnett noted that Hawaiian Holdings outperformed the airline industry on unit revenues in Q1, and sees that trend continuing in Q2. The analyst estimates Hawaiian's Q1 unit revenues increased 4%, the midpoint of its previous 3%-5% guidance, versus Imperial's industry estimate of 2.5%. Barnett maintained an Outperform rating and one-year price target of $80 on Hawaiian Holdings shares.
03/08/18
SIDC
03/08/18
UPGRADE
SIDC
Buy
Hawaiian Holdings upgraded to Buy from Neutral at Sidoti
01/30/18
IMPC
01/30/18
NO CHANGE
Target $80
IMPC
Outperform
Hawaiian Holdings price target raised to $80 from $75 at Imperial Capital
Imperial Capital analyst Michael Derchin raised his price target for Hawaiian Holdings to $80 following the company's Q4 results. The analyst increased his fiscal 2018 estimates to reflect strong unit revenues and better than expected unit costs. He keeps an Outperform rating on Hawaiian Holdings.
SHPG Shire
$164.05

3.97 (2.48%)

04/19/18
RILY
04/19/18
NO CHANGE
Target $200
RILY
Buy
Shire price target raised to $200 from $181 at B. Riley FBR
B. Riley FBR analyst David Buck raised his price target for Shire (SHPG) to $200 after the company rejected an approach from Takeda Pharmaceutical (TKPYY) and Allergan confirmed interest in a potential acquisition. The analyst keeps a Buy rating on the shares.
04/19/18
04/19/18
NO CHANGE

BTIG says Allergan may be interested in Shire after insufficient Takeda offers
BTIG analyst Timothy Chiang noted that Shire (SHPG) is trading higher after news that at least one other company other than Takeda (TKPYY) is interested in acquiring Shire, and naming Allergan (AGN) as one of those possible suitors. Chiang also believes that other companies, such as Pfizer (PFE), could entering into the bidding for Shire. BTIG maintained a Buy rating and $195 price target on Shire shares.
04/19/18
WELS
04/19/18
NO CHANGE
Target $245
WELS
Outperform
Allergan selloff on potential Shire bid understandable, says Wells Fargo
Wells Fargo analyst David Maris believes the selloff today in shares of Allergan (AGN) on news the company is considering a bid for Shire (SHPG) is understandable. Many believe Allergan was in the process of trimming, not bulking up, Maris tells investors in a research note. He believes that if CNBC's subsequent report is true and Allergan won't be making a bid, the "about-face would be an incredible turn given Allergan's press release came out just a couple hours earlier." Further, the analyst thinks investors are now left wondering what type of disruption another major integration could mean for a company that has already had significant organizational change. Maris has an Outperform rating on Allergan with a $245 price target. The stock in afternoon trading is down 4% to $159.36.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Outperform
Wells says Allergan investors likely 'relieved and confused' by Shire news
Wells Fargo analyst David Maris believes Allergan (AGN) investors will be "both relieved and confused" by the company's announcement that it was considering a bid for Shire (SHPG) being following approximately four hours later by another announcement saying that it does not intend to make an offer for Shire. After catching up with Allergan, Maris does not think the turn of events reflects a confusion or flip-flopping, but rather was the result of disclosures required by UK takeover law, and "don't reflect anything other than Allergan being caught at a bad time." He maintains an Outperform rating on Allergan shares.
KN Knowles
$11.01

-0.575 (-4.97%)

04/02/18
CHLM
04/02/18
NO CHANGE
Target $16
CHLM
Buy
Weaker Apple orders impacting Knowles near-term results, says Craig-Hallum
Craig-Hallum analyst Anthony Stoss says that weaker Apple (AAPL) orders are impacting Knowles (KN) near-term results and rumored Facebook (FB) Smart Hub launch delays is also weighing on near-term revenues. Nonetheless, the analyst reiterates a Buy rating on Knowles stock, while lowering his price target on the shares to $16 from $17.
12/20/17
PIPR
12/20/17
INITIATION
Target $15.5
PIPR
Neutral
Knowles initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Harsh Kumar started Knowles with a Neutral rating and $15.50 price target. The analyst is concerned by the company's current cost structure and lack of earnings power.
12/15/17
JPMS
12/15/17
NO CHANGE
JPMS
JPMorgan sees opportunities in Wireless Semiconductors, prefers Qorvo
JPMorgan analyst Bill Peterson believes the recent pullback in Wireless Semiconductor names, specifically Apple-exposed stocks, creates a good opportunity for investors to take long positions. The analyst sees the most upside in Qorvo (QRVO). He believes fears of production cuts and demand weakness are overblown. The December quarter and outlook for the March quarter are tracking to company expectations that have been built on conservative prospects for smartphone demand, Peterson tells investors in a research note.
12/26/17
LSCM
12/26/17
NO CHANGE
LSCM
Buy
Lake Street says Knowles more likely than Himax to be impacted by Apple weakness
Lake Street analyst Jaeson Schmidt thinks Knowles (KN) is more likely to be impacted by concerns over iPhone X shipment weakness than Himax (HIMX), which is not immune but has the advantage of Android OEMs helping to backfill revenue that may be lost with Apple (AAPL). Amid the reports of concerns over weakness in first quarter iPhone X sales, he has Buy rating on the shares of both of the aforementioned Apple suppliers.
TER Teradyne
$41.50

1.06 (2.62%)

04/04/18
UBSW
04/04/18
INITIATION
Target $49
UBSW
Neutral
Teradyne initiated with a Neutral at UBS
UBS started Teradyne with a Neutral rating and $49 price target.
01/26/18
DADA
01/26/18
NO CHANGE
Target $55
DADA
Buy
Teradyne price target raised to $55 from $48 at DA Davidson
DA Davidson analyst Thomas Diffely raised his price target on Teradyne to $55, looking past the weak Q1 outlook as a "timing issue as some revenue was pushed to 2H18 due to the annual ramp for mobility tools being delayed by a month". The analyst cites the new 20201 EPS model that calls for modest share gains and market expansion and the growth in Universal Robots segment, keeping his Buy rating on Teradyne.
03/21/18
BOFA
03/21/18
INITIATION
Target $58
BOFA
Buy
Teradyne reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Vivek Arya reinstated coverage on Teradyne with a Buy and $58 price target saying it is an attractive way to gain secular exposure to robotics/automation and as the company gains share and notes its leadership position in core semi test equipment provides stable growth.
01/26/18
NEED
01/26/18
NO CHANGE
Target $52
NEED
Buy
Teradyne price target raised to $52 from $47 at Needham
Needham analyst Y. Edwin Mok raised his price target on Teradyne to $52 and kept his Buy rating after an "upbeat" Q4 and improved outlook. Mok says the company saw no weakness in its mobility segment and continued strength in UR - Universal Robots. Despite the soft Q1 outlook, the analyst believes Teradyne will see solid growth in 2018 and beyond, with share gains in a flattish Automatic Test Equipment market, a rapidly growing UR business, and new drivers in the other test businesses.
EW Edwards Lifesciences
$134.63

-2.59 (-1.89%)

04/11/18
RHCO
04/11/18
NO CHANGE
Target $180
RHCO
Buy
Edwards Lifesciences price target raised to $180 from $150 at SunTrust
SunTrust analyst Bruce Nudell raised his price target on Edwards Lifesciences to $180, saying the company stands to benefit from its competitive edge as the Structural Heart market reaches $13B by 2030. Nudell expects Edwards Lifesciences to retain just over 50% market share while forecasting higher annual incidence of qualified for intervention aortic stenosis patients among the fast-growing elderly population. The analyst keeps his Buy rating on Edwards Lifesciences.
03/22/18
ADAM
03/22/18
NO CHANGE
Target $174
ADAM
Buy
Canaccord reiterates Edwards Lifesciences as top large-cap pick
Canaccord analyst Jason Mills reiterated his Buy rating on Edwards Lifesciences and reiterated the stock as his top large-cap pick on the heels of the company's update on its low-risk TAVR trial enrollment and upcoming SAPIEN 3 Ultra product launches. In a research note to investors, Mills said Edwards announced enrollment completion within the computed tomography, or CT, subset of the PARTNER 3 trial examining leaflet mobility of both the SAPIEN 3 valve and surgical heart valves in the low-risk patient population and provided an update on the SAPIEN 3 Ultra system launch, expecting CE Mark approval later this year vs. the previously communicated timeline of 1Q18. Mills said his research shows continued fundamental strength in Edwards' TAVR business. He said his $174 price target "could prove conservative."
02/02/18
ADAM
02/02/18
NO CHANGE
Target $174
ADAM
Buy
Edwards Lifesciences price target raised to $174 from $140 at Canaccord
Canaccord analyst Jason Mills raised his price target on Edwards Lifesciences to $174 from $140 following Q4 results. The analyst cited business fundamentals, its accelerating domestic TAVR business, and its approach to the underpenetrated structural heart markets. Mills reiterated his Buy rating on Edwards Lifesciences shares.
03/26/18
WELS
03/26/18
NO CHANGE
WELS
IPR decision a 'nice' win for Edwards Lifesciences, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen notes USPTO has determined that all claims of the '608 patent that have been asserted against Edwards Lifesciences (EW) are invalid, which the analyst sees as an important victory for the company because the '608 patent is one of Boston Scientific's (BSX) key transcatheter valve patents. While Boston Scientific will appeal the USPTO's decision on the '608 patent, Biegelsen's patent consultant believes the company's chances of overturning the decision are very low.
DLB Dolby
$65.85

-1.4 (-2.08%)

01/16/18
RILY
01/16/18
DOWNGRADE
Target $63
RILY
Neutral
Dolby downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Eric Wood downgraded Dolby Laboratories to Neutral saying the risk/reward is more balanced following the recent share rally.
09/13/17
PIPR
09/13/17
NO CHANGE
Target $52
PIPR
Neutral
Dolby's annual Apple revenue could be up to $35M, says Piper Jaffray
Apple's (AAPL) iPhone X, iPhone 8, iPhone 8 Plus and Apple TV 4K will incorporate Dolby Vision (DLB), Piper Jaffray analyst Michael Olson tells investors in a research note. While the economics are unclear, assuming a royalty of 10c-15c per iPhone, revenue would fall between $20M-$30M annually for Dolby, Olson tells investors in a research note. Apple TV sales are likely 5M-8M units per year, potentially adding another $5M to revenue, the analyst estimates. He believes the longer term impact could be more material, however, depending on adoption of Vision on other devices. Olson upped his price target on Dolby shares to $52 from $49 and keeps a Neutral rating on the name.
04/06/18
WBLR
04/06/18
NO CHANGE
WBLR
Outperform
Dolby relationship with Samsung may be strengthening, says William Blair
William Blair analyst Ralph Schackart points out that on February 25, the Samsung Galaxy S9/S9+ product line added Dolby Atmos to its smartphones. Dolby Atmos was launched in 2012 with a focus on the movie theater end-market, Schackart tells investors in a research note. The analyst views the development as potentially early evidence that the "historically rocky Samsung/Dolby relationship may be strengthening." He estimates the Atmos opportunity for Dolby in 2018 at roughly $8M in sales and about 6c in earnings per share. Schackart keeps an Outperform rating on Dolby.
04/03/18
DOTC
04/03/18
NO CHANGE
Target $75
DOTC
Buy
Dolby investments have reached payoff stage, says Dougherty
Dougherty analyst Steven Frankel said Dolby is battling a perception that it is tied to legacy technologies, but he believes investors have missed a resurging growth story as the company's multi-year investments in new technologies have reached the payoff stage. The idea of Dolby being a double-digit revenue grower "has gone from aspirational when first trotted out by management a couple of years ago to something that looks achievable," contends Frankel, who reiterated a Buy rating and $75 price target on Dolby shares.
WYNN Wynn Resorts
$189.70

-3.54 (-1.83%)

03/23/18
03/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) and Wynn Macau (WYNMF) were upgraded to Buy from Hold at Union Gaming. 2. Cisco (CSCO) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Rod Hall saying as market volatility increases, Cisco provides a "relatively defensive" name in the sector. 3. General Mills (GIS) upgraded to Positive from Neutral at Susquehanna. 4. MPLX (MPLX) upgraded to Overweight from Equal Weight and Dominion Midstream (DM) upgraded to Equal Weight from Underweight at Morgan Stanley. 5. KB Home (KBH) upgraded to Outperform from Market Perform at Wells Fargo with analyst Stephen East saying the shares have fallen 25% since January 11, the worst in the group, while estimates "must rise." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/02/18
04/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Hold from Underperform at Jefferies with analyst Philippe Houchois saying Tesla shares are down 32% from their September 2017 peak and he sees a "high probability" that management and the board, when releasing first quarter unit data this week, take "more drastic action" on guidance and funding to "restore credibility." 2. Allstate (ALL) upgraded to Market Perform from Underperform at Keefe Bruyette with analyst Meyer Shields expecting strong first quarter results from the company. 3. Discovery (DISCA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying she believes the stock offers a "compelling" risk/reward profile at current share levels. 4. Darden (DRI) was upgraded to Outperform from Sector Perform at RBC Capital and to Outperform from Market Perform at Raymond James. 5. Wynn Resorts (WYNN) upgraded to Buy from Neutral at Roth Capital with analyst David Bain saying he views regulatory and other risks as diminished, with Massachusetts likely remaining as the largest one still outstanding. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/02/18
ROTH
04/02/18
UPGRADE
Target $206
ROTH
Buy
Wynn Resorts upgraded to Buy from Neutral at Roth Capital
Roth Capital analyst David Bain upgraded Wynn Resorts to Buy from Neutral as he views regulatory and other risks as diminished, with Massachusetts likely remaining as the largest one still outstanding. While the analyst does not believe the "Steve Wynn stock multiple premium" will return, fundamental underpinnings are too strong for shares to not retrace at least closer to historical stock multiple averages in the near-to-intermediate term. Bain also raised his price target on the shares to $206 from $170.
03/27/18
JPMS
03/27/18
NO CHANGE
Target $214
JPMS
Overweight
Wynn Resorts price target raised to $214 from $196 at JPMorgan
JPMorgan analyst Joseph Greff raised his price target for Wynn Resorts to $214 after increasing his 2018 and 2019 Macau property level EBITDA estimates by 3%. The analyst sees "continued healthy growth" in Macau and Wynn-specific premium mass momentum. Greff sees an "increasingly favorable" risk/reward on shares of Wynn Resorts following the "recent risk-reducing events" over the past month. He keeps an Overweight rating on the name.
COF Capital One
$97.41

-0.115 (-0.12%)

03/27/18
UBSW
03/27/18
INITIATION
UBSW
Buy
Capital One initiated with a Buy at UBS
UBS analyst Eric Wasserstrom initiated Capital One with a Buy rating and $114 price target. Wasserstrom sees the company benefiting from "inverse growth math." Additionally, the analyst believes positive EPS revisions may support "moderate multiple expansion by about 1.5 P/E turns to 11.5x."
04/05/18
SBSH
04/05/18
INITIATION
Target $115
SBSH
Buy
Capital One initiated with a Buy at Citi
Citi analyst Jill Shea started Capital One Financial with a Buy rating and $115 price target. The analyst is bullish on the company's efficiency improvement from its tech investments. She expects more tangible benefits as Capital One moves to the cloud and closes data centers.
04/05/18
04/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spotify (SPOT) initiated with a Buy at Canaccord and Stifel. 2. Trade Desk (TTD) initiated with an Overweight at Piper Jaffray. 3. Saul Centers (BFS) initiated with a Neutral at B. Riley FBR. 4. Capital One (COF) and American Express (AXP) were initiated with a Buy at Citi while Discover (DFS) and Synchrony (SYF) were initiated with a Neutral. 5. Intel (INTC) initiated with a Buy at UBS while Qualcomm (QCOM) was initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/18
WELS
03/29/18
NO CHANGE
Target $109
WELS
Outperform
Capital One price target lowered to $109 from $117 at Wells Fargo
Wells Fargo analyst Donald Fandetti lowered his price target for Capital One to $109 from $117 ahead of quarterly results. The analyst reiterates an Outperform rating on the shares.
SGMO Sangamo
$17.85

-0.3 (-1.65%)

02/22/18
WELS
02/22/18
NO CHANGE
Target $39
WELS
Outperform
Wells sees 'significant upside potential' in Sangamo, ups target to $39
Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics (SGMO) to $39 from $30 following the company's cell therapy collaboration with Gilead Sciences (GILD). The analyst sees "significant upside potential" in Sangamo and would be buyers of the stock at current levels. He believes the collaboration is validation of a "potential best-in-class" gene editing platform and provides "significant option value" on exposure to next-generation cell therapies with Gilead. Birchenough reiterates an Outperform rating on Sangamo. The stock in midday trading is up 21%, or $4.75, to $26.96.
02/23/18
JEFF
02/23/18
NO CHANGE
Target $33
JEFF
Buy
Sangamo price target raised to $33 from $18 at Jefferies
Jefferies analyst Maury Raycroft raised his price target for Sangamo Therapeutics (SGMO) citing the "favorable" terms of the Gilead Sciences (GILD) collaboration. The deal unlocks "substantial potential" for Sangamo, Raycroft tells investors in a research note. He keeps a Buy rating on the shares.
03/07/18
LEHM
03/07/18
NO CHANGE
Target $59
LEHM
Overweight
Crispr Therapeutics price target raised to $59 from $29 at Barclays
Barclays analyst Gena Wang raised her price target for Crispr Therapeutics (CRSP) to $59 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Crispr shares and keeps an Overweight rating on the name.
04/10/18
JEFF
04/10/18
NO CHANGE
JEFF
Jefferies sees value in Abeona, Sangamo, Ultragenyx after AveXis deal
Jefferies analyst Maury Raycroft believes Novartis' (NVS) acquisition of AveXis (AVXS) provides additional validation for the progress and potential of gene therapy. The deal brings attention to Abeona Therapeutics (ABEO) specifically, based on the company's use of AAV9, which is the same vector AveXis has been evaluating with its lead program AVXS-101, Raycroft tells investors in a research note. He thinks yesterday's takeover puts an updated value on gene therapy, implying long-term potential and "sufficient de-risking has occurred." The analyst feels the premium paid for AveXis shows value in Abeona, Sangamo (SGMO) and Ultragenyx (RARE).
MRTX Mirati Therapeutics
$28.25

-0.15 (-0.53%)

03/12/18
LEHM
03/12/18
INITIATION
Target $44
LEHM
Overweight
Mirati Therapeutics initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Mirati Therapeutics with an Overweight rating and $44 price target. The company's lead candidate, sitravatinib, has shown promising initial activity in checkpoint refractory non-small-cell lung carcinoma patients, when combined with nivolumab, the analyst contends. She believes Mirati has a solid pipeline with large commercial potential.
03/05/18
SBSH
03/05/18
NO CHANGE
Target $37
SBSH
Buy
Mirati Therapeutics price target raised to $37 from $23 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Mirati Therapeutics to $37 saying the company's KRAS G12C inhibitor, "albeit preclinical, seems to have the right stuff." We understand several pharma players have expressed substantial early interest in Mirati's KRAS program, Nochomovitz tells investors in a research note. He added the program to his model with a 10% probability of success and calls it a "must watch." The analyst keeps a Buy rating on Mirati Therapeutics.
03/12/18
HCWC
03/12/18
NO CHANGE
Target $40
HCWC
Buy
Mirati Therapeutics price target raised to $40 from $21 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics to $40 ahead of several data readouts expected in mid-2018. The analyst's new target represents a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for sitravatinib and mocetinostat. He keeps a Buy rating on Mirati.
03/09/18
RHCO
03/09/18
NO CHANGE
Target $40
RHCO
Buy
Mirati Therapeutics price target raised to $40 from $20 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Mirati Therapeutics to $40, recalibrating his model based on the management's positive view of the company's lead candidate product. Lawson keeps his Buy rating, stating that while it is still early, investors are interested in the KRAS program as it pertains to targeting lung, colorectal and pancreatic cancer market.

TODAY'S FREE FLY STORIES

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

LNC

Lincoln National

$68.89

-0.555 (-0.80%)

16:24
05/25/18
05/25
16:24
05/25/18
16:24
Syndicate
Breaking Syndicate news story on Lincoln National »

Lincoln National files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGLY

Digital Ally

$2.63

0.075 (2.94%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Digital Ally »

Digital Ally files $25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNGX

Soligenix

$1.58

-0.005 (-0.32%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Soligenix »

Soligenix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$35.34

0.08 (0.23%)

16:21
05/25/18
05/25
16:21
05/25/18
16:21
Hot Stocks
HFF Inc. announces $640M sale of 5 Bryant Park office tower in Manhattan »

HFF announces the $640M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/25/18
05/25
16:20
05/25/18
16:20
Options
Closing CBOE SPX and VIX Index summary for May 25th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.